UnicoCell Biomed is dedicated to advancing the allogeneic adipose-derived stem cell drug, ELIXCYTE®, targeting irreversible diseases associated with aging. This includes its approval by the TFDA and FDA for the indication of knee osteoarthritis, with ongoing Phase III clinical trials. Concurrently, the drug has received approval for Phase I/II trials for chronic kidney disease, which have been completed and are now in the data analysis stage. ELIXCYTE® not only demonstrates exceptional clinical trial outcomes but also has successfully published its research findings in international journals. We are actively collaborating with medical institutions to conduct clinical trials and expand patient recruitment, aiming to expedite the completion of the clinical phase and achieve drug certification.

˙ Clinical data indicates lasting effects, eliminating the need for long-term medication and frequent follow-up visits.
˙ Alleviates inflammation, relieves pain, and reduces swelling.
˙ Eliminates the risks associated with surgical infections and complications.
˙ Minimizes harm from chemical drugs